Corcept Therapeutics said on Monday its experimental combination ovarian cancer drug improved survival in patients with a ...

A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.

A phase 3 trial of nemvaleukin alfa in with Keytruda for patients with platinum-resistant ovarian cancer will not continue on ...

In a study co-led by the University of Maryland School of Medicine (UMSOM), researchers have identified a "master regulator" ...

Antibody-drug conjugates and their development remains a central theme in ongoing research within the realm of ovarian cancer ...

Results from a new Phase 3 trial published in the journal npj Precision Oncology found that a cancer stem cell test can accurately choose more effective treatments and lead to improved outcomes for ...

Chemotherapy regimens chosen by the ChemoID assay dramatically increased ORR in patients with platinum-resistant ovarian cancer.

A new drug combination from Corcept Therapeutics, relacorilant, has shown potential in treating platinum-resistant ovarian ...

Ovarian cancer, a leading cause of death among gynecological malignancies, has a poor prognosis and low 5-year survival rate, ...

Corcept Therapeutics (CORT) stock shot up over 100% yesterday as markets reacted to the company’s announcement of promising outcomes from its ...

In a study co-led by the University of Maryland School of Medicine (UMSOM), researchers have identified a “master regulator” ...